Pipeline biosimilar for asthma meets primary endpoint in P2/3 study
In Brief Biosimilar News reports that Sorrento’s experimental anti-IgE biosimilar, STI-004, met it’s primary endpoint in a 32-week, Phase 2/3 study conducted in China. ?Patients who rec…
